Urine sample

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
49Systemic lupus erythematosus4
51Scleroderma2
61Autoimmune hemolytic anemia1
IDDisease name (Link within this page)Number of trials
63Idiopathic thrombocytopenic purpura1
84Sarcoidosis1

49. Systemic lupus erythematosus


Clinical trials : 1,414 / Drugs : 1,077 - (DrugBank : 181) / Drug target genes : 130 - Drug target pathways : 209 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

51. Scleroderma


Clinical trials : 740 / Drugs : 813 - (DrugBank : 165) / Drug target genes : 140 - Drug target pathways : 231 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

61. Autoimmune hemolytic anemia


Clinical trials : 218 / Drugs : 186 - (DrugBank : 42) / Drug target genes : 27 - Drug target pathways : 158 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

63. Idiopathic thrombocytopenic purpura


Clinical trials : 868 / Drugs : 544 - (DrugBank : 96) / Drug target genes : 82 - Drug target pathways : 195 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

84. Sarcoidosis


Clinical trials : 196 / Drugs : 261 - (DrugBank : 78) / Drug target genes : 73 - Drug target pathways : 183 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries